MedTrace Logo

Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

NCT02781506 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-08-08

Study results available
· View outcomes & findings →

Summary

Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose variable, in 1-3 fractions.

Conditions

  • Metastatic Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Nivolumab

Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist

RADIATION

SAbR

SAbR (1-3 lesions)

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Raquibul Hannan, MD, PhD · UT Southwestern Medical Center at Dallas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-20
Primary Completion
2021-05-24
Completion
2021-05-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781506 on ClinicalTrials.gov